484 related articles for article (PubMed ID: 24702306)
1. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.
Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD
J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306
[TBL] [Abstract][Full Text] [Related]
2. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Molden E; Skovlund E; Braathen P
Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
[TBL] [Abstract][Full Text] [Related]
5. Potentially inappropriate prescribing to hospitalised patients.
Radosević N; Gantumur M; Vlahović-Palcevski V
Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):733-7. PubMed ID: 18050360
[TBL] [Abstract][Full Text] [Related]
6. Prescribing patterns and predictors of high-level polypharmacy in the elderly population: A prospective surveillance study from two teaching hospitals in India.
Harugeri A; Joseph J; Parthasarathi G; Ramesh M; Guido S
Am J Geriatr Pharmacother; 2010 Jun; 8(3):271-80. PubMed ID: 20624616
[TBL] [Abstract][Full Text] [Related]
7. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies.
Molden E; Garcia BH; Braathen P; Eggen AE
Eur J Clin Pharmacol; 2005 Apr; 61(2):119-25. PubMed ID: 15692832
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
Milner E; Ainsworth M; Gleaton M; Bookstaver D
J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese National Health Insurance program.
Lai HY; Hwang SJ; Chen YC; Chen TJ; Lin MH; Chen LK
Clin Ther; 2009 Aug; 31(8):1859-70. PubMed ID: 19808145
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Potential and Clinically Relevant Statin-Drug Interactions in Frail and Robust Older Inpatients.
Thai M; Hilmer S; Pearson SA; Reeve E; Gnjidic D
Drugs Aging; 2015 Oct; 32(10):849-56. PubMed ID: 26442861
[TBL] [Abstract][Full Text] [Related]
11. [Risk of pharmacological interactions due to the co-administration of statins and cytochrome P450 isoenzyme 3A4-metabolized drugs: multicentre, crossover study].
Mostaza JM; Lahoz C; Morales-Olivas F; Pinto X; Tranche S; Suarez-Tembra M; Mantilla T; Rius J
Med Clin (Barc); 2014 Nov; 143(10):427-32. PubMed ID: 24216013
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
13. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm.
Finks SW; Campbell JD
Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525
[TBL] [Abstract][Full Text] [Related]
14. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.
Tirkkonen T; Ryynänen A; Vahlberg T; Irjala K; Klaukka T; Huupponen R; Laine K
Drug Saf; 2008; 31(3):231-40. PubMed ID: 18302447
[TBL] [Abstract][Full Text] [Related]
15. [Concomitant use of statins and cytochrome P 450 inhibitors in Croatia].
Reiner Z; Galić M; Hanzevacki M; Tedeschi-Reiner E
Lijec Vjesn; 2005; 127(3-4):65-8. PubMed ID: 16193855
[TBL] [Abstract][Full Text] [Related]
16. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.
Mannheimer B; von Bahr C; Pettersson H; Eliasson E
Ther Drug Monit; 2008 Oct; 30(5):565-9. PubMed ID: 18728628
[TBL] [Abstract][Full Text] [Related]
17. Role of P-glycoprotein in statin drug interactions.
Holtzman CW; Wiggins BS; Spinler SA
Pharmacotherapy; 2006 Nov; 26(11):1601-7. PubMed ID: 17064205
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia.
Bhattacharya R; Chatterjee S; Carnahan RM; Aparasu RR
Am J Geriatr Pharmacother; 2011 Dec; 9(6):434-41. PubMed ID: 22030114
[TBL] [Abstract][Full Text] [Related]
19. Physical Performance and Quality of Life in Older Adults: Is There Any Association between Them and Potential Drug Interactions in Polymedicated Octogenarians.
Verde Z; García de Diego L; Chicharro LM; Bandrés F; Velasco V; Mingo T; Fernández-Araque A
Int J Environ Res Public Health; 2019 Oct; 16(21):. PubMed ID: 31671923
[TBL] [Abstract][Full Text] [Related]
20. Review of prescription medications in home-based older adults with stroke: a pilot study.
Classen S; Meuleman J; Garvan C; Ried LD; Mann W; Asal N
Res Social Adm Pharm; 2007 Mar; 3(1):104-22. PubMed ID: 17350560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
